Frank Jiang | CEO
CStone | China

Frank Jiang, CEO, CStone

Frank Jiang, MD, PhD joined CStone Pharmaceuticals in July, 2016 as its CEO. CStone Pharmaceuticals is a Chinese biotech company focused on addressing the most important patient needs in China and beyond. With immuno-oncology as CStone's core therapeutic focus, the company strives to lead Chinese research to the global market through its world class R&D team, its innovative portfolio, and an open innovation strategy.

Prior to CStone, Dr. Jiang has over a decade of experience working in China. He first joined Sanofi China in 2006, where he built up its clinical research capabilities that significantly reduced the drug lag in Sanofi China‘s portfolio. He also set up several collaborations with top Chinese academic institutions to develop innovative medicines in China. In 2010, Dr. Jiang was promoted to Head of Asia Pacific R&D (including Japan) for Sanofi, where he was responsible for developing and implementing regional R&D strategies focused on building a pipeline to meet the emerging needs of patients in the APAC region.

Before coming to China, Dr. Jiang was with Sanofi US where he headed a 21,000-patient clinical trial (EXTRACT) comparing enoxaparin with unfractionated heparin for acute myocardial infarction, which resulted in the successful global registration.

Prior to Sanofi, Dr. Jiang was at Eli Lilly, where he led a global Phase II trial with an anti-inflammatory agent for the treatment of patients with severe sepsis.

Dr. Jiang received his MD from Nanjing Medical University and a PhD in Immunology from the University of British Columbia. He went on to complete a clinical residency in Internal Medicine and a fellowship in Laboratory Medicine at Washington University School of Medicine, where he subsequently served on the faculty of Internal Medicine and Emergency Medicine.


Phar-East Day One @ 11:00

Cancer precision medicine: From screening to drug selection and development

  • Personalised, affordable and high efficacy are the ideal criteria of a medicine. But the big question is how do we actually move towards providing highly personalised medicine to patients in need?
  • Investigate the pathway to the future of medicine, from drug discovery, development to reaching out to the patients.

back to speakers